Sanofi said to weigh alternative deals to Medivation; eyes BioMarin Pharmaceutical - sources
French pharmaceutical giant Sanofi is working on a back up plan in case it fails to win its $9.3 billion hostile pursuit of US-listed Medivation.
Top sources have told me the French pharmaceutical giant has begun looking at US-based rare disease specialist BioMarin Pharmaceutical as a potential alternative takeover deal after growing frustrated in its pursuit of Medivation, which has so far resisted the French company's advances...
Register
Register for free to see rest of this article and all public articles from Betaville
Login / RegisterDate: Friday, 17 June 2016, 12:00 am